512-64-1
中文名稱
醌霉素A
英文名稱
QUINOMYCIN A
CAS
512-64-1
分子式
C51H64N12O12S2
分子量
1101.26
MOL 文件
512-64-1.mol
更新日期
2024/08/21 17:38:37
512-64-1 結(jié)構(gòu)式
基本信息
中文別名
棘霉素醌霉素A
英文別名
SK-302Bnsc526417
NSC 13502
ECHINOMYCIN
QUINOMYCIN A
echinomycina
Echinomycin >97%
Antibiotic A 654I
Echinomycin (NSC-13502)
EchinoMycin, Actinoleukin, 1491, 59266, X 948, X 53III
物理化學(xué)性質(zhì)
熔點(diǎn)217-218℃
比旋光度D20 -310° (c = 0.86 in chloroform)
密度1.0964 (rough estimate)
折射率1.6700 (estimate)
儲(chǔ)存條件-20°C
儲(chǔ)存條件2-8°C
溶解度溶于DMSO（高達(dá)5mg/ml）
形態(tài)白色固體
顏色白色至米色
Merck13,3531
穩(wěn)定性可在-20°C下DMSO溶液中保存長達(dá)3個(gè)月
安全數(shù)據(jù)
警示詞危險(xiǎn)
危險(xiǎn)性描述H301+H311+H331-H361
危險(xiǎn)品標(biāo)志T
危險(xiǎn)類別碼46-23/24/25
安全說明53-36/37/39-45
危險(xiǎn)品運(yùn)輸編號(hào)UN 3462 6.1/PG 2
危險(xiǎn)品運(yùn)輸編號(hào)UN 3462 6.1/PG 2
WGK Germany3
WGK Germany3
RTECS號(hào)JW5250000
F10
危險(xiǎn)等級(jí)6.1(b)
包裝類別III
海關(guān)編碼2941900000
醌霉素A價(jià)格(試劑級(jí))
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2024/11/08 | HY-106101 | 醌霉素A Echinomycin | 512-64-1 | 1mg | 2880元 |
常見問題列表
生物活性
Echinomycin (Quinomycin A) 是一種有效的,細(xì)胞滲透性的低氧誘導(dǎo)因子-1 (HIF-1) DNA 結(jié)合活性的小分子抑制劑。Echinomycin 選擇性抑制癌癥干細(xì)胞，其 IC50 值為 29.4 pM。體外研究
Echinomycin (0-10 nM; 16 hours; U251 cells) treatment significantly inhibits hypoxia-induced VEGF mRNA expression in a dose-dependent fashion. Echinomycin very potently inhibits hypoxic induction of luciferase expression in U251-HRE in a dose-dependent fashion with an EC 50 of 1.2 nM.
RT-PCR
| Cell Line: | U251 cells |
| Concentration: | 0 nM, 0.625 nM, 1.25 nM, 5 nM, 10 nM |
| Incubation Time: | 16 hours |
| Result: | Significantly inhibited VEGF mRNA expression induced by hypoxia in a dose-dependent fashion. |
體內(nèi)研究
Echinomycin (10 μg/kg; intravenous injection; for 40 days; NOD-SCID mice) treatment efficiently eradicates mouse lymphoma and serially transplantable human acute myeloid leukemia (AML) in xenogeneic model by preferential elimination of cancer stem cells (CSCs). HIF1α maintains mouse lymphoma CSCs by repressing a negative feedback loop in the Notch pathway.
| Animal Model: | NOD-SCID mice received 1.8Gy of irradiation and i.v. injection with peripheral blood cells from patients AML-71 and AML-150 |
| Dosage: | 10 μg/kg |
| Administration: | Intravenous injection; for 40 days |
| Result: | Efficiently eradicated mouse lymphoma and serially transplantable human AML in xenogeneic model by preferential elimination of CSCs. |